(Q38102914)

28 August 2017

title

Advanced-stage pancreatic cancer: therapy options (English)

1 reference

28 August 2017

1 reference

6

Markus W Büchler

1 reference

28 August 2017

5

Thilo Hackert

1 reference

28 August 2017

3

Christoph Springfeld

1 reference

28 August 2017

2

Stephanie E Combs

1 reference

28 August 2017

Jens Werner

1

1 reference

28 August 2017

Werner Hartwig

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

30 April 2013

1 reference

Nature Reviews Clinical Oncology

28 August 2017

published in

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

323-333

1 reference

28 August 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

National failure to operate on early stage pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Pancreatic cancer surgery in the new millennium: better prediction of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Total pancreatectomy for pancreatic cancer: indications and operative technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Redefining the R1 resection in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Hospital volume and surgical mortality in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Hospital volume and late survival after cancer surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

The prognostic and predictive value of serum CA19.9 in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Computed tomography perfusion analysis of pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Resectability of pancreatic adenocarcinoma in patients with locally advanced disease downstaged by preoperative therapy: a challenge for MDCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Palliative resections versus palliative bypass procedures in pancreatic cancer--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Bypass surgery versus palliative pancreaticoduodenectomy in patients with advanced ductal adenocarcinoma of the pancreatic head, with an emphasis on quality of life analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Quality of life in pancreatic cancer: analysis by stage and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Biliary stenting versus bypass surgery for the palliation of malignant distal bile duct obstruction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Predictors of survival in patients with malignant gastric outlet obstruction: A patient-oriented decision approach for palliative treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Surgical versus endoscopic palliation of malignant gastric outlet obstruction: big incision, little incision, or no incision?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Neoadjuvant radio-chemotherapy in advanced primarilynon-resectable carcinomas of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Neoadjuvant therapy in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Stereotactic body radiation therapy for nonresectable tumors of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Particle therapy at the Heidelberg Ion Therapy Center (HIT) - Integrated research-driven university-hospital-based radiation oncology service in Heidelberg, Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Particle radiation therapy using proton and heavier ion beams

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Systemic treatment of advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Treatment options for advanced pancreatic cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Albumin-bound paclitaxel: a next-generation taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

The pancreas cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Stromal biology and therapy in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Targeted therapies: how personal should we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Is personalization of care coming to pancreatic oncology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Monoclonal antibodies and other targeted therapies for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Vaccines for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Oncolytic virotherapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Most Pancreatic Cancer Resections are R1 Resections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

[Carcinoma of the pancreas: summary of guidelines 2007, issued jointly by 15 German specialist medical societies]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Multivisceral resections in pancreatic cancer: identification of risk factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Vascular resection in pancreatic cancer surgery: survival determinants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Borderline Resectable Pancreatic Cancer: Definitions and the Importance of Multimodality Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

The "artery first" approach for resection of pancreatic head cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Preliminary experience with the hanging maneuver for pancreaticoduodenectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Uncinate process first--a novel approach for pancreatic head resection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Long-Term Results of Resection of Adenocarcinoma of the Body and Tail of the Pancreas Using Radical Antegrade Modular Pancreatosplenectomy Procedure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: perineural growth more important prognostic factor than tumor localization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Multidetector CT evaluation of the course of nonresectable pancreatic carcinomas with neoadjuvant therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Outcome of microscopically nonradical, subtotal pancreaticoduodenectomy (Whipple's resection) for treatment of pancreatic head tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

R2 resection in pancreatic cancer--does it make sense?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Crossing the Rubicon: when pancreatic resection with curative intent ends in an R2 status. Impact of "desmoplastic pseudo-pancreatitis" and anatomical site of irresectability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Bypass surgery versus intentionally incomplete resection in palliation of pancreatic cancer: is resection the lesser evil?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: Feasibility and clinical preliminary results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Strategien für präoperatives Downsizing bei inoperablem Pankreaskarzinom

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Induction Gemcitabine and Stereotactic Body Radiotherapy for Locally Advanced Nonmetastatic Pancreas Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Proton beams to replace photon beams in radical dose treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK01

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.66

Palliative treatment in "peri"-pancreatic carcinoma: stenting or surgical therapy?

31 March 2020

1 reference

12 December 2020

Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer

1 reference

12 December 2020

Left posterior approach to the superior mesenteric vascular pedicle in pancreaticoduodenectomy for cancer of the pancreatic head

1 reference

12 December 2020

Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index

1 reference

12 December 2020

Management of borderline resectable pancreatic adenocarcinoma

1 reference

12 December 2020

Intensity-modulated radiotherapy for pancreatic adenocarcinoma

1 reference

12 December 2020

In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines

1 reference

12 December 2020

10.1038/NRCLINONC.2013.66

Identifiers

DOI

1 reference

28 August 2017

1 reference